Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESO-101 versus placebo in adults with active eosinophilic esophagitis
NL-OMON52665Phase 2Recruiting
- Sponsor
- EsoCap AG
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ESO-101 and mometasone in eosinophilic esophagitis (EoE) (2 arms), sponsored by EsoCap AG. Primary endpoint: Absolute change in peak eosinophil count from baseline to end of treatment. Started Nov 2021; status: recruiting.
02
Drugs
ESO-101mometasone
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON52665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52665.